ECSP099641A - Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709 - Google Patents

Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709

Info

Publication number
ECSP099641A
ECSP099641A EC2009009641A ECSP099641A ECSP099641A EC SP099641 A ECSP099641 A EC SP099641A EC 2009009641 A EC2009009641 A EC 2009009641A EC SP099641 A ECSP099641 A EC SP099641A EC SP099641 A ECSP099641 A EC SP099641A
Authority
EC
Ecuador
Prior art keywords
relates
benzotiophenes
heteroarilo
benzofurans
replaced
Prior art date
Application number
EC2009009641A
Other languages
English (en)
Spanish (es)
Inventor
Erwan Arzel
David Wensbo
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP099641A publication Critical patent/ECSP099641A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
EC2009009641A 2007-03-06 2009-09-21 Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709 ECSP099641A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89314907P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
ECSP099641A true ECSP099641A (es) 2009-10-30

Family

ID=39738510

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009641A ECSP099641A (es) 2007-03-06 2009-09-21 Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709

Country Status (23)

Country Link
US (1) US7772256B2 (enExample)
EP (1) EP2132201B1 (enExample)
JP (1) JP5631009B2 (enExample)
KR (1) KR101530392B1 (enExample)
CN (2) CN102617556A (enExample)
AR (1) AR065599A1 (enExample)
AU (1) AU2008221668B2 (enExample)
BR (1) BRPI0808503B8 (enExample)
CA (1) CA2680157C (enExample)
CL (1) CL2008000645A1 (enExample)
CO (1) CO6220965A2 (enExample)
EC (1) ECSP099641A (enExample)
ES (1) ES2615381T3 (enExample)
IL (1) IL200524A0 (enExample)
MX (1) MX2009009469A (enExample)
MY (1) MY147347A (enExample)
NZ (1) NZ579157A (enExample)
PE (1) PE20090164A1 (enExample)
SA (1) SA08290097B1 (enExample)
TW (1) TW200901998A (enExample)
UA (1) UA98481C2 (enExample)
UY (1) UY30951A1 (enExample)
WO (1) WO2008108730A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
EP2300481B1 (en) 2008-05-30 2015-09-30 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2388255A1 (en) * 2010-05-11 2011-11-23 Ikerchem, S.L. Polysubstituted benzofurans and medicinal applications thereof
JP5825608B2 (ja) * 2010-08-06 2015-12-02 国立大学法人京都大学 ピリジルベンゾフラン誘導体
MX2020008082A (es) * 2018-02-05 2020-09-24 Univ Strasbourg Compuestos y composiciones para el tratamiento del dolor.
BR112021026837A2 (pt) * 2019-08-06 2022-02-22 Domain Therapeutics Compostos de 5-heteroaril-piridin-2-amina como anta-gonistas do receptor de neuropeptídeo ff

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
CA2176127A1 (en) * 1993-12-21 1995-06-29 William Henry Walker Lunn Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5518713A (en) 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
SI1334091T1 (sl) 2000-08-24 2013-01-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
US20040077654A1 (en) * 2001-01-15 2004-04-22 Bouillot Anne Marie Jeanne Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
JP4307001B2 (ja) * 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
KR20040058111A (ko) 2001-04-23 2004-07-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아밀로이드 플라크 응집 억제제 및 진단 영상화제
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
AU2003242233A1 (en) 2002-06-12 2003-12-31 Bf Research Institute, Inc. Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
ATE425753T1 (de) 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
JPWO2004087641A1 (ja) 2003-03-31 2006-06-29 第一製薬株式会社 ヒドラゾン誘導体
CN100372844C (zh) 2003-05-13 2008-03-05 弗·哈夫曼-拉罗切有限公司 作为腺苷受体配体的2-咪唑-苯并噻唑
EP1644365A2 (en) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006251832A1 (en) 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
WO2007035405A2 (en) 2005-09-16 2007-03-29 University Of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
SI1945622T1 (sl) 2005-10-11 2012-05-31 Univ Pittsburgh Izotopično markirane spojine benzfurana kot označevalne snovi za amiloidogenske proteine
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び/又は沈着に起因する疾患の診断薬及び治療薬
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
EP2125800A1 (en) 2007-01-22 2009-12-02 AstraZeneca AB Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes

Also Published As

Publication number Publication date
MY147347A (en) 2012-11-30
KR20090117892A (ko) 2009-11-13
IL200524A0 (en) 2010-04-29
CO6220965A2 (es) 2010-11-19
EP2132201A1 (en) 2009-12-16
RU2009133257A (ru) 2011-04-20
AR065599A1 (es) 2009-06-17
CL2008000645A1 (es) 2008-10-24
CN101675042B (zh) 2012-06-13
KR101530392B1 (ko) 2015-06-22
US7772256B2 (en) 2010-08-10
US20080221149A1 (en) 2008-09-11
CA2680157A1 (en) 2008-09-12
TW200901998A (en) 2009-01-16
AU2008221668B2 (en) 2011-03-31
JP2010520276A (ja) 2010-06-10
BRPI0808503B1 (pt) 2020-09-29
WO2008108730A1 (en) 2008-09-12
AU2008221668A1 (en) 2008-09-12
CN102617556A (zh) 2012-08-01
BRPI0808503B8 (pt) 2021-05-25
EP2132201A4 (en) 2011-05-25
PE20090164A1 (es) 2009-05-03
UY30951A1 (es) 2008-10-31
EP2132201B1 (en) 2016-11-16
UA98481C2 (en) 2012-05-25
NZ579157A (en) 2012-04-27
ES2615381T3 (es) 2017-06-06
CN101675042A (zh) 2010-03-17
CA2680157C (en) 2016-04-12
JP5631009B2 (ja) 2014-11-26
SA08290097B1 (ar) 2011-10-29
MX2009009469A (es) 2009-09-15
BRPI0808503A2 (pt) 2014-08-19

Similar Documents

Publication Publication Date Title
ECSP099641A (es) Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
WO2009155017A3 (en) Novel substituted azabenzoxazoles
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
MX2016016384A (es) Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.
MY165906A (en) Phenothiazine diaminium salts and their use
BRPI0608387A2 (pt) compostos para o tratamento de doenças inflamatórias
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
CO6311099A2 (es) Derivados de benzofurano benzotiofeno benzotiazol como moduladores de fxr
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
PH12015502323A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
HRP20070505B1 (hr) Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva
MX2018006370A (es) Inhibidores de proteina quinasa, metodo de preparacion y su uso medico.
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR079641A1 (es) Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
EP2436666A4 (en) PROCESS FOR OBTAINING NOVEL DERIVATIVES OF NAPHTALES FOR IN VIVO-DIAGNSOE OF ALZHEIMER DISEASE
MY160075A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
WO2010051196A8 (en) Novel substituted azabenzoxazoles
MX2009009113A (es) Nuevos indoles 2-heteroaril sustituidos 695.
WO2006020156A3 (en) Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease
MX2025010406A (es) Aglutinantes de alfa-sinucleina y metodos de uso